• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Understanding the biology of urothelial cancer metastasis.了解尿路上皮癌转移的生物学机制。
Asian J Urol. 2016 Oct;3(4):211-222. doi: 10.1016/j.ajur.2016.09.005. Epub 2016 Sep 14.
2
High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis.尿路上皮癌中高基质SFRP2表达提示预后不良。
Front Oncol. 2022 Mar 16;12:834249. doi: 10.3389/fonc.2022.834249. eCollection 2022.
3
Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.尿路上皮癌干细胞与上皮可塑性:膀胱癌的当前概念及治疗意义
Cancer Metastasis Rev. 2015 Dec;34(4):691-701. doi: 10.1007/s10555-015-9589-6.
4
Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells.同步放化疗对膀胱尿路上皮癌细胞转移和间质转化的影响。
Anticancer Res. 2021 Oct;41(10):4957-4968. doi: 10.21873/anticanres.15309.
5
Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.上尿路尿路上皮癌与膀胱尿路上皮癌的基因组特征比较
Oncologist. 2021 Aug;26(8):e1395-e1405. doi: 10.1002/onco.13839. Epub 2021 Jun 8.
6
Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.肿瘤干性评分用于评估上皮间质转化(EMT)和癌症干细胞(CSCs)特征,并预测膀胱癌的预后和免疫治疗反应。
Stem Cell Res Ther. 2023 Feb 1;14(1):15. doi: 10.1186/s13287-023-03239-1.
7
Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.上尿路和膀胱尿路上皮癌的全面基因组分析。
Eur Urol Focus. 2021 Nov;7(6):1339-1346. doi: 10.1016/j.euf.2020.08.001. Epub 2020 Aug 26.
8
Urothelial cancer gene regulatory networks inferred from large-scale RNAseq, Bead and Oligo gene expression data.从大规模RNA测序、微珠和寡核苷酸基因表达数据推断出的尿路上皮癌基因调控网络。
BMC Syst Biol. 2015 May 14;9:21. doi: 10.1186/s12918-015-0165-z.
9
WNT7B represses epithelial-mesenchymal transition and stem-like properties in bladder urothelial carcinoma.WNT7B 抑制膀胱尿路上皮癌中的上皮-间充质转化和干细胞样特性。
Biochim Biophys Acta Mol Basis Dis. 2022 Jan 1;1868(1):166271. doi: 10.1016/j.bbadis.2021.166271. Epub 2021 Sep 22.
10
OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.OVOL2 通过精细调控鼻咽癌中的上皮-间充质转化来连接干性和转移。
Theranostics. 2018 Mar 8;8(8):2202-2216. doi: 10.7150/thno.24003. eCollection 2018.

引用本文的文献

1
Metastatic cardiac tumor resulting in cardiogenic shock from muscle-invasive urothelial carcinoma of the bladder: a case report.转移性心脏肿瘤导致膀胱肌层浸润性尿路上皮癌引发的心源性休克:一例报告
Urol Case Rep. 2025 Aug 25;62:103178. doi: 10.1016/j.eucr.2025.103178. eCollection 2025 Sep.
2
Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer.评估淋巴结清扫在变异型亚型膀胱癌中的治疗作用。
Cancers (Basel). 2025 Jul 31;17(15):2536. doi: 10.3390/cancers17152536.
3
Intravesical Therapy for Upper Urinary Tract Urothelial Carcinoma: A Comprehensive Review.上尿路尿路上皮癌的膀胱内治疗:一项综述
Cancers (Basel). 2023 Oct 17;15(20):5020. doi: 10.3390/cancers15205020.
4
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.帕博利珠单抗单药治疗不可切除性尿路上皮癌日本患者的安全性和有效性:一项全国性上市后监测。
BMC Cancer. 2023 Jun 20;23(1):565. doi: 10.1186/s12885-023-10930-2.
5
Comparative oncology: overcoming human cancer through companion animal studies.比较肿瘤学:通过伴侣动物研究攻克人类癌症。
Exp Mol Med. 2023 Apr;55(4):725-734. doi: 10.1038/s12276-023-00977-3. Epub 2023 Apr 3.
6
Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in chemotherapy and suppresses tumor growth and muscle invasion.hsa-miR-30a-3p 克服膀胱癌化疗获得性保护性自噬,抑制肿瘤生长和肌肉浸润。
Cell Death Dis. 2022 Apr 21;13(4):390. doi: 10.1038/s41419-022-04791-z.
7
MicroRNA‑34a‑5p serves as a tumor suppressor by regulating the cell motility of bladder cancer cells through matrix metalloproteinase‑2 silencing.微小 RNA-34a-5p 通过沉默基质金属蛋白酶-2 来调节膀胱癌细胞的运动性,从而发挥肿瘤抑制作用。
Oncol Rep. 2021 Mar;45(3):911-920. doi: 10.3892/or.2020.7910. Epub 2020 Dec 24.
8
Collision tumors of the lung: A case report of urothelial carcinoma metastasizing to renal cell carcinoma with heterotopic ossification.肺碰撞瘤:一例尿路上皮癌转移至肾细胞癌伴异位骨化的病例报告。
Respir Med Case Rep. 2020 Nov 20;31:101297. doi: 10.1016/j.rmcr.2020.101297. eCollection 2020.
9
TP53INP2 Modulates Epithelial-to-Mesenchymal Transition via the GSK-3β/β-Catenin/Snail1 Pathway in Bladder Cancer Cells.TP53INP2通过GSK-3β/β-连环蛋白/Snail1信号通路调控膀胱癌细胞的上皮-间质转化
Onco Targets Ther. 2020 Sep 28;13:9587-9597. doi: 10.2147/OTT.S251830. eCollection 2020.
10
Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro.体外实验证实,慢性依维莫司应用诱发的膀胱癌转移可被萝卜硫素拮抗。
Int J Mol Sci. 2020 Aug 4;21(15):5582. doi: 10.3390/ijms21155582.

本文引用的文献

1
Patient-derived xenografts as in vivo models for research in urological malignancies.患者来源异种移植作为泌尿生殖系统恶性肿瘤研究的体内模型。
Nat Rev Urol. 2017 May;14(5):267-283. doi: 10.1038/nrurol.2017.19. Epub 2017 Feb 21.
2
GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.GON4L通过YY1-雄激素受体-CD24轴驱动癌症生长。
Cancer Res. 2016 Sep 1;76(17):5175-85. doi: 10.1158/0008-5472.CAN-16-1099. Epub 2016 Jun 16.
3
Androgen receptor (AR) promotes male bladder cancer cell proliferation and migration via regulating CD24 and VEGF.雄激素受体(AR)通过调节CD24和血管内皮生长因子(VEGF)促进男性膀胱癌细胞的增殖和迁移。
Am J Transl Res. 2016 Feb 15;8(2):578-87. eCollection 2016.
4
Recent advances in immuno-oncology and its application to urological cancers.免疫肿瘤学的最新进展及其在泌尿系统癌症中的应用。
BJU Int. 2016 Oct;118(4):506-14. doi: 10.1111/bju.13518. Epub 2016 Jun 3.
5
MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer.微小RNA-429通过恢复膀胱癌中E-钙黏蛋白的表达来逆转上皮-间质转化。
Oncotarget. 2016 May 3;7(18):26593-603. doi: 10.18632/oncotarget.8557.
6
Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis.saRNA介导的靶向p53激活可抑制人膀胱癌细胞的生长和转移。
J Exp Clin Cancer Res. 2016 Mar 25;35:53. doi: 10.1186/s13046-016-0329-8.
7
Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.膀胱癌临床侵袭性微乳头变异型的基因表达谱
Eur Urol. 2016 Oct;70(4):611-620. doi: 10.1016/j.eururo.2016.02.056. Epub 2016 Mar 15.
8
Tetrandrine reverses epithelial-mesenchymal transition in bladder cancer by downregulating Gli-1.汉防己甲素通过下调Gli-1逆转膀胱癌中的上皮-间质转化。
Int J Oncol. 2016 May;48(5):2035-42. doi: 10.3892/ijo.2016.3415. Epub 2016 Mar 3.
9
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.浆细胞样变异型膀胱癌中频繁出现的体细胞CDH1功能丧失突变。
Nat Genet. 2016 Apr;48(4):356-8. doi: 10.1038/ng.3503. Epub 2016 Feb 22.
10
c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling.c-Met和CREB1通过调节Akt/GSK-3β/Snail信号通路参与miR-433介导的膀胱癌上皮-间质转化抑制作用。
Cell Death Dis. 2016 Feb 4;7(2):e2088. doi: 10.1038/cddis.2015.274.

了解尿路上皮癌转移的生物学机制。

Understanding the biology of urothelial cancer metastasis.

作者信息

Kobayashi Takashi

机构信息

Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

出版信息

Asian J Urol. 2016 Oct;3(4):211-222. doi: 10.1016/j.ajur.2016.09.005. Epub 2016 Sep 14.

DOI:10.1016/j.ajur.2016.09.005
PMID:29264189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5730871/
Abstract

Management of unresectable urothelial cancer (UC) has been a clinical challenge for decades. While drug resistance is a key issue, precise understanding of biology of UC metastasis is another challenge for the improvement of treatment outcome of UC patients. Introduction of the cell biology concepts including epithelial-mesenchymal transition (EMT) and cancer stemness seems to explain UC metastasis. Molecular genetics based on gene expression profiling, next generation sequencing, and explosion of non-coding RNA world has opened the door to intrinsic molecular subtyping of UC. Next steps include, based on the recently accumulated understanding, the establishment of novel disease models representing UC metastasis in various experimental platforms, particularly animal systems. Indeed, novel knowledge molecular genetics has not been fully linked to the modeling of UC metastasis. Further understanding of bladder carcinogenesis is needed particularly with regard to cell of origin related to tumor characteristics including driver gene alterations, pathological differentiations, and metastatic ability. Then we will be able to establish better disease models, which will consequently lead us to further understanding of biology and eventually the development of novel therapeutic strategies for UC metastasis.

摘要

几十年来,不可切除性尿路上皮癌(UC)的治疗一直是一项临床挑战。虽然耐药性是一个关键问题,但精确了解UC转移的生物学特性是改善UC患者治疗效果的另一项挑战。引入包括上皮-间质转化(EMT)和癌症干性在内的细胞生物学概念似乎可以解释UC转移。基于基因表达谱分析、下一代测序以及非编码RNA领域的蓬勃发展的分子遗传学为UC的内在分子分型打开了大门。接下来的步骤包括,基于最近积累的认识,在各种实验平台,特别是动物系统中建立代表UC转移的新型疾病模型。事实上,分子遗传学的新知识尚未与UC转移的建模完全联系起来。需要进一步了解膀胱致癌作用,特别是与肿瘤特征相关的起源细胞,包括驱动基因改变、病理分化和转移能力。然后我们将能够建立更好的疾病模型,这将进而使我们进一步了解生物学,并最终开发出针对UC转移的新型治疗策略。